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Abstract In view of the trend towards personalized treatment
strategies for (cancer) patients, there is an increasing need to
noninvasively determine individual patient characteristics.
Such information enables physicians to administer to patients
accurate therapy with appropriate timing. For the noninvasive
visualization of disease-related features, imaging biomarkers
are expected to play a crucial role. Next to the chemical de-
velopment of imaging probes, this requires preclinical studies
in animal tumour models. These studies provide proof-of-
concept of imaging biomarkers and help determine the phar-
macokinetics and target specificity of relevant imaging
probes, features that provide the fundamentals for translation
to the clinic. In this review we describe biological processes
derived from the Bhallmarks of cancer^ that may serve as
imaging biomarkers for diagnostic, prognostic and treatment
response monitoring that are currently being studied in the
preclinical setting. A number of these biomarkers are also
being used for the initial preclinical assessment of new inter-
vention strategies. Uniquely, noninvasive imaging approaches
allow longitudinal assessment of changes in biological pro-
cesses, providing information on the safety, pharmacokinetic
profiles and target specificity of new drugs, and on the
antitumour effectiveness of therapeutic interventions. Preclin-
ical biomarker imaging can help guide translation to optimize
clinical biomarker imaging and personalize (combination)
therapies.
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Introduction
In connection with the increasing trend towards personalized
medicine, the development of imaging biomarkers and quan-
titative imaging techniques has been identified as a major
research priority in medical imaging communities [1–4]. Ad-
hering to the definition of a biomarker proposed by the Bio-
markers Definitions Working Group [5], an imaging biomark-
er is: BA characteristic that can be objectively measured from
imaging data as an indicator of normal biological processes,
pathogenic processes, or pharmacological responses to a ther-
apeutic intervention^. In the clinical as well as the preclinical
research setting, imaging biomarkers can be a measure of
anatomical, physiological/functional or molecular characteris-
tics (Table 1). Anatomical and functional imaging biomarkers,
such as imaging-based tumour size measurements and tumour
perfusion measurements, are routinely used in clinical studies,
but are less commonly used in preclinical studies, and vice
versa, the use of molecular imaging biomarkers is more com-
mon in preclinical studies. The latter often require the use of
new chemical entities that require preclinical evaluation be-
fore they become safely applicable in humans [6].
Preclinical studies are very important to obtain more in-
sight into and a better understanding of biological and
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pathological processes and to perform initial assessments of
the therapeutic potential of newly developed drugs. Classical-
ly, such studies have been performed using large groups of
animals and killing them at various time-points followed by
histopathological examination of harvested tissue. With the
current availability of high-resolution and highly sensitive
preclinical imaging technologies many biological and patho-
logical tissue characteristics can now be noninvasively and
longitudinally assessed in living animals (Table 2). Not only
does this allow reduced animal use, but it also provides more
accurate information compared to the classical technologies
[7, 8]. With the availability of animal imaging systems similar
to clinical imaging systems, preclinical studies offer valuable
options in providing proof-of-concept in the development pro-
cess of new imaging biomarkers for clinical use.
Next to imaging systems, imaging agents are of crucial
importance in biomedical imaging. Most commonly they are
contrast agents and tracers that show accumulation at the tar-
get site after binding to receptor structures. Alternatively, spe-
cific enzymatic cleavage mechanisms may be exploited. Ex-
amples include: radiotracers, fluorescent molecules, paramag-
netic ions or combinations thereof [9–18]. Small particles,
including nanoparticles, liposomes and microbubbles, that
can be (non)covalently bound to targetingmolecules have also
been developed [17, 19–23]. Such vectors are promising in the
area of drug delivery and MRI, optical and photoacoustic
imaging, contrast-enhanced ultrasonography and ultrasound
molecular imaging, and thermoablative therapy [17, 19,
23–25]. Examples include ligand-functionalized polymer-
shelled microcapsules [26] and mixed liposome/peptide/
DNA (LPD) nanocomplexes [27] for nuclear and optical im-
aging as well as for MRI, illustrating the versatile potential of
targeted and differentially labelled particles as research tools
in cancer imaging.
In cancer research, the search for and use of imaging bio-
markers has been strongly connected with the Bhallmarks of
cancer^ defined in the past two decades (Fig. 1) [28, 29].
These hallmarks are considered crucial characteristics of tu-
mours that define their level of malignancy and/or responsive-
ness for treatment. As such these characteristics can be con-
sidered indicative of a patient’s prognosis. Impressive devel-
opments in the areas of imaging technology and imaging
tracers have strengthened preclinical imaging studies on the
hallmarks of cancer. Following these hallmarks, in this review
we describe the state of the art and future perspectives of
imaging biomarkers in preclinical in vivo oncological studies,
Table 1 Examples of typical imaging biomarkers
Type Characteristic Imaging method References
Anatomical Tumour size/morphology MRI, CT, US [157]
Physiological/functional Vessel density CE MRI, CE CT, CE US [205, 206]
Vessel functionality CE MRI, CE CT, CE US [206–207]
Cellular integrity DW MRI [185]
Molecular Metabolic activity/metabolites FDG PET/MRS [209–210]
Receptor expression PET, SPECT, USMI, optical [74, 118, 119, 125, 128, 130, 195]
Enzymatic activity PET, SPECT, MRI, optical [18, 175, 177, 179]
MRI magnetic resonance imaging, CT computed tomography, US ultrasonography, PET positron emission tomography, CE contrast-enhanced, DW
diffusion-weighted, FDG fluoro-D-glucose, MRS magnetic resonance spectroscopy, USMI ultrasound molecular imaging
Table 2 Overview of common in vivo small-animal imaging modalities
Technology Means of
detection
Resolution Depth Quantitative Agents Target Relative cost
CT Ionizing radiation
(X-rays)
50 μm No limit Yes Iodinated molecules Anatomical,
physiological
€€
PET Ionizing radiation
(γ-rays)
1 – 2 mm No limit Yes 19F-, 64Cu-, 68Ga-, or 11
C-labelled compounds
Physiological,
molecular
€€
SPECT Ionizing radiation
(γ-rays
0.3 – 1 mm No limit Yes 99mTc-, 111In-, 67Ga-labelled
compounds
Physiological,
molecular
€€
MRI Electromagnetism 10 – 100 μm No limit Yes Paramagnetic and magnetic
compounds (iron oxide;
chelated Gd3+)
Anatomical,
physiological
€€€
US Acoustic waves 50 μm Centimetres Yes Microbubbles Anatomical €
Optical Light 1 – 5 mm <3 cm Yes Luciferine, fluorochromes Physiological,
molecular
€
Adapted from: de Jong et al. [8]
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as well as recent successful translation into the clinic. We also
address specific challenges encountered in preclinical research
regarding the influence of animal handling techniques on re-
search findings. Due to the focus on hallmarks and due to
space constraints, we were not able to cover fully the
extensive field of tumour imaging using tumour-specific
markers, for example somatostatin receptors (SSTR), epider-
mal growth factor receptors (EGFR) and oestrogen receptors.
Many of these markers are addressed in more detail in other,
more clinically oriented, chapters of this special issue, and
Fig. 1 Hallmarks of cancer and imaging biomarkers (1 uncontrolled proliferation, 2 angiogenesis, 3 altered metabolism, 4 invasion and metastasis, 5
inflammation and immune cells, 6 cell death)
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have also been discussed in various recent excellent reviews
[30–33], to which the reader is referred to.
Imaging biomarkers for the Bhallmarks of cancer^
Imaging proliferation/growth
Rapid and uncontrolled proliferation is the primary hallmark
of cancer and underlies various other characteristics of tu-
mours, e.g. angiogenesis and altered metabolic profiles [34].
High proliferative activity is often linked to tumour aggres-
siveness and is therefore considered a biomarker suitable for
prognosis [35]. Furthermore, in radiotherapy-based treatment
strategies the proliferative index of tumours is further consid-
ered a predictive biomarker of response. Reduction in prolif-
erative activity in tumours, on the other hand, may function as
a biomarker for therapeutic response assessment, especially
with treatment strategies that have a primarily cytostatic effect.
Consequently, significant effort has been dedicated to the de-
velopment and validation of imaging biomarkers for tumour
cell proliferation. Nuclear imaging techniques based on prob-
ing the so-called thymide salvage pathway, using tracers such
as 11C-FMAU, 18F-FLT, and 76Br-BFU, are well-known ex-
amples for proliferation imaging [36]. In both preclinical [36]
and clinical [35, 37] studies significant correlations have been
found between uptake of these tracers and proliferative activ-
ity determined in tissue biopsies ex vivo. These tracers are still
under investigation for their use as imaging biomarkers for
early treatment response assessment. In various preclinical
studies major decreases in 18F-FLT uptake were observed fol-
lowing antitumour treatment [38–41]. In these studies de-
crease in 18F-FLT uptake also coincided with reduced prolif-
erative activity or reduced tumour growth. However, despite
the fact that similar observations were made in clinical studies,
various limitations of these techniques have also been identi-
fied, including incorporation into mitochondrial DNA instead
of nuclear DNA and high uptake in liver and bone marrow.
These characteristics limit the specificity of these tracers for
actual tumour cell proliferation. For FLT, a specific limitation
is the fact that 18F-FLT is not incorporated into DNA at all, but
is only trapped in the cytosol [42]. FLT uptake is in that sense
not directly related to DNA synthesis. This may be a main
reasonwhy in various forms of cancer no relationship between
18F-FLT uptake and proliferative index or response to treat-
ment has been found [35, 43, 44]. Because of the encountered
limitations of these thymidine analogues alternative ap-
proaches for cell proliferation imaging have been explored.
Recent efforts in this respect include probing of type II topo-
isomerase (Topo-II) activity and expression levels of the
sigma-2 receptor.
Topo-II is an ATP-dependent enzyme that is involved in
cell cycle control and is essential in transcription, replication
and chromosome segregation processes, and shows overex-
pression of one of its isoforms (Topo-IIα) in various types
of cancer [45–47]. Next to being an attractive target for mo-
lecular therapy, Topo-II is therefore also considered an attrac-
tive target for imaging cell proliferation [45–48]. Some recent
preclinical studies have shown the basic feasibility of gener-
ating imaging probes for Topo-IIα. Further development and
optimization of these probes is required though, since the
tracers generated to date show unfavourable biodistribution
in vivo [48, 49].
Another recently proposed target that may be suitable as an
imaging marker of cell proliferation is the sigma-2 receptor.
Sigma receptors are upregulated in rapidly proliferating cells,
with the sigma-2 receptor being specifically overexpressed in
proliferating tumour cells, i.e. tenfold compared to quiescent
tumour cells [50]. Because of this specificity of sigma-2 re-
ceptor expression in actual proliferating tumour cells, it offers
unique options in tumour imaging. Current efforts are there-
fore dedicated to the development of suitable imaging probes
for the sigma-2 receptor [51–53]. A promising tracer in this
respect is [18F]ISO-1. Uptake of this tracer has been shown to
be significantly correlated with Ki-67 expression in animal
models [54, 55], as well as in a first in-patient study [56]. In
a recent preclinical imaging study, Shoghi et al. [57] evaluated
the usefulness of this tracer in the measurement of the prolif-
erative status of tumours and as a marker of early response. In
two breast cancer xenograft models, they observed significant
correlations between tumour uptake of the radiolabelled li-
gands and growth and proliferative status of the tumours
(Fig. 2).
In conclusion, currently no validated imaging probe for the
noninvasive assessment of the proliferative status of tumours
exists. Recent preclinical studies have identified some poten-
tial relevant targets and generation and evaluation of probes
specific for these targets are underway.
Imaging tumour angiogenesis
Since angiogenesis is a critical process related to tumour
growth and metastasis, a vast amount of effort has been put
into the development and validation of imaging techniques for
visualization and quantification of vessel density and vascular
functionality, using (dynamic) contrast-enhanced imaging
techniques. Angiogenesis is an imaging biomarker applied
in tumour diagnosis and in the prediction and assessment of
treatment response [58–60]. In recent years these techniques
have also been increasingly used in the preclinical cancer re-
search setting, including studies regarding the assessment of
novel antiangiogenic treatment strategies, drug delivery stud-
ies and tumour model validation [61–63]. However, given the
lack of standardization of these techniques and uncertainty in
the interpretation of the derived parameters, which also holds
true in the clinical setting, preclinical studies are also focused
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on defining the technological aspects of these techniques
[64–66].
In the era of molecular medicine, molecular imaging ap-
proaches in general, including techniques for the assessment
of angiogenesis and angiogenic processes, have been receiv-
ing increasing attention. So with the elucidation of molecular
processes in angiogenesis, various imaging targets have been
identified and are under investigation (Table 3). Often these
involve membrane proteins expressed by endothelial cells, but
proteins involved in angiogenesis and expressed by tumour
cells or stromal cells are also targets of interest. Two of the
most interesting targets in this respect are carbonic anhydrase
IX [67, 68] and hypoxia-inducible factor-1 [69]. In many
cases these targets are not only considered as imaging targets,
but also as targets for treatment [70–72]. Avariety of imaging
methods, including PET, SPECT, MRI, ultrasonography and
optical imaging, have been used in molecular imaging
strategies.
A technique that has recently been gaining a lot of ground
in these applications is ultrasound molecular imaging using
targeted microbubbles (Fig. 3) [25, 73, 74]. In genetically
modified mouse models, VEGFR2-targeted microbubbles
have been shown to detect precancerous tissue, such as liver
dysplasia [75] and breast hyperplasia. Ultrasound molecular
imaging has also shown potential as an early response marker
in several cancer types [76–79]. In recent studies the superi-
ority of ultrasound molecular imaging over functional vascu-
lar imaging and tumour size measurements for response mon-
itoring has been demonstrated in selected tumour models [80,
81]. This technique is now on its way to the clinic; a recent
Fig. 2 Characterization of the pharmacokinetics of [18F]ISO-1 and
in vitro determination of sigma-2 receptor density in a rat model of mam-
mary tumour induced by injection of N-methyl-N-nitrosourea. a Two-
hour summed images show two tumours and the submandibular gland
(S/M). The liver is evident in the coronal slices. b Time–activity curves of
the two tumours, muscle and the left ventricular blood pool (inset shows
the kinetics during the initial 5 min). c Representative saturation binding
experiments which show the total bound, nonspecific bound and specific
bound [18F]ISO-1. d Representative Scatchard plots which were used to
determine the equilibrium dissociation constant (Kd), the maximum num-
ber of binding sites (Bmax) and the Hill coefficient (nH). Reprinted from
Shoghi et al. [57]
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phase 0 clinical trial demonstrated that VEGFR2-targeted
microbubbles can be successfully used for prostate cancer
imaging [82] and to have the potential for monitoring patients
at high risk of cancer, such as aggressive primary hepatocel-
lular carcinoma [83]. In the preclinical setting new develop-
ments in this field involve the use of 3D imaging techniques
and microbubbles functionalized with ligands specific for
tumour-specific markers (Fig. 3).
Additional molecular imaging strategies regarding the use
of imaging biomarkers for the assessment of tumour angio-
genesis involve imaging approaches to assess tissue hypoxia,
a physiological effect strongly linked to the aberrant tissue
Fig. 3 Ultrasound molecular imaging of tumour angiogenesis. a 3D
images of a nonresponding (top) and a responding (bottom) pancreatic
tumour in mice on day 0 and day 2 after aurora A kinase inhibitor
treatment. The green colour represents the signal from the αvβ3-
targeted microbubbles which is overlain on the black and white B-mode
ultrasound image. b The group ofWillmann has overcome the problem of
poor expression of human cancer-specific endothelial markers in murine
models by developing a mouse model that expresses human vascular
biomarkers. They transfected mouse endothelial cells with the human
biomarker of interest and implanted these with the tumour cells of inter-
est. Using this method, Foygel et al. [232] expressed human thymocyte
differentiation antigen 1 (Thy 1 or CD90) in pancreatic ductal adenocar-
cinoma. Left The Thy1-targeted microbubble (MBThy1) signal (colour-
coded scale in arbitrary units) overlain on black and white B-mode ultra-
sound images is strong in Thy1-positive tumour, whilst there is only
background signal in both types of control tumour. Centre There is also
low signal from control-targeted microbubbles (MBControl; green circles
tumour regions). Right Corresponding immunofluorescence micrographs
(ex vivo) of merged double-stained sections (red murine CD31, green
human Thy1), confirming human Thy1 expression on neovasculature in
Thy1-positive tumours (yellow). Scale bars: 5 mm (left and centre),
50 μm (right). Reprinted from Tsurata et al. [233]
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vasculature in many tumours [84]. Tumour oxygenation can
be imaged by optical techniques [85, 86], MRI [67, 87–89],
photoacoustic techniques [90] and nuclear techniques [91,
92]. These approaches are inmost cases based on the detection
of haemoglobin saturation using techniques such as BOLD
MRI, or accumulation of tracers following a reduction reac-
tion by which the reduced molecule becomes entrapped or
bound within tumour cells or tissue, for example with
nitroimidazole-based probes.
In view of current antiangiogenic treatment strategies mo-
lecular imaging of angiogenic processes is very much in fo-
cus. At the preclinical level various targets have been identi-
fied and are currently being evaluated. A number of these have
also entered clinical testing, but data obtained so far have not
resulted in consistent and conclusive results, and more studies
are warranted.
Imaging cellular energetics
Rapid cell growth and hypoxic conditions are considered driv-
ing forces behind altered energy metabolism, as is often found
in tumours. However, oncogenetically driven processes have
also been described as underlying causes of altered energy
metabolism. In tumours, specifically the high degree of reli-
ance on glucose as the metabolic substrate and the so-called
Warburg effect provide a basis for metabolism imaging. The
Warburg effect entails the phenomenon of aerobic glycolysis,
where even under normoxic conditions tumour cells convert
glucose into lactate. The preferred use of glucose as substrate
in many tumour types is the reason for the avid uptake of
fluorodeoxyglucose (FDG) and the reason for the high clinical
value of 18F-FDG in cancer diagnostics and treatment re-
sponse monitoring. The use of FDG as imaging biomarker
for tumour localization, prognosis and response has been ad-
dressed in various excellent clinical reviews to which the read-
er is referred to [93–95].
Because some limitations in the use of 18F-FDG PET have
also been recognized, e.g. accumulation in non-tumour tissue
and limited uptake in slow-growing tumours such as prostate
cancer and neuroendocrine tumours, alternative methods for
metabolic profiling are also under investigation. Since tumours
may also display changes in protein and phospholipid metabo-
lism, these processes also provide imaging targets [96–98].
New insights into the role of amino acids and amino acid trans-
porters have instigated the development and evaluation of new
radiolabelled amino acids, as recently reviewed by Huang and
McConathy [96]. Findings of altered phospholipid metabolism
have resulted in the development and testing of radiolabelled
choline analogues [99, 100]. Schwarzenbock et al. [101] recent-
ly addressed the issue of sensitivity and specificity of three such
tracers in a xenograft prostate cancer model in mice. They
found that the new tracer [11C]SMC performs better than the
clinically used [11C]CHO. Emonds et al. on the other hand
reported a potential limitation of choline-based tracers [102].
Comparing [11C]CHO and [11C]acetate in androgen-dependent
and androgen-independent prostate cancer xenograft models,
they found that androgen deprivation influences the uptake of
[11C]CHO, and warned of the risk of underestimation of the
presence of recurrent prostate cancer following androgen dep-
rivation therapy.
Magnetic resonance spectroscopy (MRS) has played a ma-
jor role in metabolic profiling of tumours for several decades
[103]. However, due to issues regarding sensitivity and the
need for specialized techniques, MRS has not yet evolved as
a routine clinical practice. Nonetheless, MRS approaches con-
tinue to be explored for certain types of cancer [104] with
recent increasing interest in its use in prostate cancer [105,
106] and breast cancer [107, 108]. The interest in MRS-
based assessment of tumour metabolism has recently under-
gone a further boost by the newly developed technique of
hyperpolarized MRI [109]. This technique is based on MRS
imaging of 13C-labelled cell substrates that have undergone
dynamic nuclear polarization (or hyperpolarization). The hy-
perpolarization step has the big advantage of enhancing the
sensitivity of detection of 13C-labelled compounds by more
than 10,000-fold [110], by which one of the main limitations
of 13C-MRS can be overcome, thus allowing sensitive assess-
ment of the dynamics of metabolic processes in vivo. This
technique has opened up new possibilities in studying meta-
bolic pathways in tumours by which a better understanding of
the sometimes controversial metabolic signatures in tumours
can be obtained [111]. Also, the potential use of this technique
for response assessment in cancer therapy was recently dem-
onstrated. Rodrigues et al. found highly tumour-specific con-
version of hyperpolarized [U-2H, U-13C]glucose to lactate and
a marked decrease in the lactate/glucose ratio 24 h after treat-
ment with the chemotherapeutic drug etoposide in murine
tumour models of lymphoma and lung tumours (Fig. 4)
[112]. In prostate cancer cell lines, Canapè et al. [113] dem-
onstrated the ability of hyperpolarized NMR, using
[5-13C]glutamine as a probe, to noninvasively assess
glutaminolysis. They were also able to show that the rate of
Table 3 Selected examples of molecular targets as imaging biomarkers
of angiogenesis
Target Preclinical/Clinical use References
Integrins Clinical, preclinical [73, 212–219]
VEGFR2 Clinical, preclinical [76, 220–222]
VEGF Preclinical [223, 224]
Tumour endothelial
marker 8 (TEM8)
Preclinical [225, 226]
CD147 Preclinical [227–229]
CD276 Preclinical [230]
EGFR Preclinical [227, 231]
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glutaminolysis in prostate tumour cell lines changed depend-
ing on their survival response after treatment with cytostatic
drugs, and therefore argued that hyperpolarized [5-13C]gluta-
mine metabolism is a promising biomarker for the noninva-
sive detection of tumour response to treatment.
In conclusion, imaging of the metabolic profile of tumours
has already been part of clinical routine in cancer management.
Current techniques, however, still have various limitations re-
garding sensitivity, specificity or applicability, and additional
and alternative methods are needed. Various promising new
techniques are under evaluation and multimodal imaging ap-
proaches may solve some the issues encountered [114].
Imaging tumour evasion and metastasis
One of the most critical factors in clinical cancer management
is the degree of tumour evasion and the occurrence of (distant)
metastasis. These features determine if local or systemic ther-
apies are required and may be the basis for palliative rather
than curative therapy. Routine molecular imaging technology
using 18F-FDG (molecular marker: increased sugar metabo-
lism) has revolutionized the noninvasive detection of tumour
extent and metastatic spread for a great number of cancers (see
above). Unfortunately, this highly generic approach is not al-
ways effective, meaning that some cancer types require more
Fig. 4 13C spectroscopic
imaging showing the spatial
distribution of labelled glucose
and lactate in EL4 and LL2
tumour-bearing mice. a Repre-
sentative 13C MR spectra ac-
quired from subcutaneous EL4
and LL2 tumours, brain, heart,
liver and kidneys 15 s after injec-
tion of 0.35 mL 100 mM
hyperpolarized [U-2H,
U-13C]glucose. The lactate spec-
tra are the sum of four transients
collected over 1 s, whereas a sin-
gle transient was acquired for the
glucose spectra. Flux of the
hyperpolarized 13C label was only
observed between [U-2H,
U-13C]glucose (63 – 99 ppm) and
lactate C1 (doublet at about
185 ppm) in EL4 and LL2 tu-
mours. b Representative chemical
shift selective images obtained
about 15 s after intravenous in-
jection of 0.4 mL 200 mM
hyperpolarized [U-2H,
U-13C]glucose into an EL4
tumour-bearing mouse. The spa-
tial distribution of glucose, urea
and lactate are shown as voxel
intensities relative to their respec-
tive maxima. The 1H MR images,
shown in grey scale, were used to
define the anatomical location of
the tumour (outlined in white). A
urea phantom was included to
serve as a reference. The colour
scales represent arbitrary linearly
distributed intensities for the
hyperpolarized images. Reprinted
from Rodrigues et al. [112]
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dedicated techniques. One example is the sentinel node pro-
cedure that is focused on the identification of (submillimetre)
micrometastasis in the lymphatic track using lymphatic flow
and accumulation by the immune system as molecular
markers [115]. Early studies have shown that more personal-
ized means to monitor the extent of oncological disease may
benefit greatly from the use of molecular tumour markers
[116–118]. As indicated in the Introduction, many clinical
success stories in molecular imaging of specific cancer bio-
markers can be found in which tumour-specific markers, such
as SSTR-targeting peptides and HER-2 (EGFR2)-targeting
antibodies, have been used [119–121]
A number of molecular targets are considered to be repre-
sentative of metastatic disease and have provided the basis for
the development and recent translation of innovative imaging
agents. These targets include prostate-specific membrane an-
tigen (PSMA), chemokine receptor 4 (CXCR4) and mesen-
chymal–epithelial transition factor (c-MET). PSMA is
expressed both on the primary tumour and on prostate
cancer-related metastasis, so it has the potential to visualize
the full tumour load, including metastasis [122]. PSMA-based
imaging agents described are based on molecules that differ in
size, e.g. antibodies, nanobodies, aptamers and low molecular
weight inhibitors of PSMA [116, 123–127]. The last of these
in particular have shown high potential in mice and more
recently also in humans [116]. Important to note here is that
clinical PSMA PET is so effective that it might rapidly replace
choline-based PET [128]. Although clinical trials with optical
derivatives have not yet been reported, it has already become
clear from preclinical studies that these small molecules re-
main efficient when a fluorescent dye is attached [129].
Based on the potential to drive migration along a stromal
derived factor 1 (SDF-1) gradient, CXCR4 is considered a
marker of malignant/metastatic disease. High expression
levels of SDF-1 have been found at the most common sites
of cancer metastasis, e.g. lymph nodes, lungs, liver and bone
marrow. This makes CXCR4 a candidate target for molecular
imaging to define the extent of disease and/or to identify high-
ly aggressive subpopulations of tumour cells [130, 131]. Pre-
clinical molecular imaging of CXCR4 is focused around
SPECT, PET and optical imaging. Where the first two have
shown potential for the noninvasive visualization of disease
extent [132, 133], the last enables microscopic evaluation of
receptor interactions and has demonstrated potential in image-
guided surgery applications [134]. Studies regarding this re-
ceptor nicely illustrate that the efforts to optimize affinity and
kinetics have paid off. Of all the new compounds tested in the
preclinical setting, to our knowledge only one has made it to
use in humans, namely [68Ga]pentixafor [135]
MET (a receptor tyrosine kinase) is an oncogene that plays
a role in tumour metastasis and motility [136]. Tyrosine kinase
MET is the receptor for hepatocyte growth factor (HGF/SF)
and interaction between MET HGF/SF can induce scattering
and migration of (tumour) progenitor cells. The general oc-
currence on carcinomas makes MET a marker for metastatic
risk stratification. MET imaging has been pursued using dif-
ferent targeting moieties and different imaging labels. For ex-
ample, anticalins and antibodies have been used to generate
PET tracers for this receptor [137, 138]. Both show activity
in vitro and in mouse tumour models. Alternatively, peptides
have been used to optically visualize MET in mice. Examples
are the linear peptide cMBP-AOC-Cy5.5 [139] and the cyclic
peptide GE137 (that also contains a Cy5-like dye) [140]. To
our knowledge only the latter has so far found its way into
clinical trials, where it has shown potential for fluorescence-
guided surgery of colorectal neoplasia.
In conclusion, the recent successful development of tracers
for PSMA, CXCR and c-MET indicates the value that explor-
atory preclinical studies have in the field of molecular imag-
ing. Given the many ongoing preclinical imaging efforts, it is
highly likely that more tracers for metastatic disease will find
their way into the clinic. When this is the case, it is of course
critical that they are evaluated beyond exploratory first-in-
human studies. Ultimately, (randomized) multicentre studies
will be required to prove the clinical value of the new
technologies.
Imaging inflammation and (evasion of) immune cells
Tumours harbour dynamic microenvironments in which can-
cer cells are associated with normal host cells. The tumour-
associated stroma plays an important role during tumour
growth, influencing events such as angiogenesis, metastasis
and immune suppression [28, 141, 142]. As such, the stroma
forms an attractive target for diagnostic and therapeutic appli-
cations. To distinguish normal from cancer cells, different
strategies can be followed. Mice and other animal models
can be created that use genetic reporters to label or track spe-
cific cells within the tumour or cells can be labelled with
tumour-targeting or high-affinity molecules that contain radio-
nuclides, fluorochromes or magnetic labels. Different myeloid
cells are important components of the tumour stroma.Myeloid
cells are frequently found to infiltrate tumours and have been
linked to diverse tumour-promoting activities. In particular,
tumour-associated macrophages (TAMs) are an important
component of the tumour stroma [143]. Macrophages are
plastic cells that can adopt different phenotypes depending
on the immune context; microenvironmental stimuli can drive
a macrophage either towards a Bclassical^ (M1) or an
Balternative^ (M2) activation state, two extremes in a spec-
trum. M1 macrophages are typically characterized by the ex-
pression of proinflammatory cytokines, inducible nitric oxide
synthase 2 and MHC class II molecules. M2 macrophages
have a decreased level of these molecules, are identified by a
malignant phenotype and their signature expression of a vari-
ety of markers, including arginase-1 and mannose and several
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receptors. Strongly proangiogenic TAMs that reside in hypox-
ic tumour areas express high levels of macrophage mannose
receptor (CD206) [144, 145].
It has been suggested that TAMs display an M2-like phe-
notype [144]. However, because of a lack of specific imaging
agents, there is a poor understanding of their absolute num-
bers, flux rates and functional states in different tissues. Mo-
lecular probes for macrophage imaging target several aspects
of macrophage cell biology. Cellular probes specific for mem-
brane markers on the cell surface can localize macrophages
within tissues, and surface proteins whose levels increase in
stimulated cells can preferentially identify activated cells. Sur-
face targets for macrophage imaging, although not specific for
this cell type, include vascular cell adhesion protein-1 [146],
receptors (folate receptor, SSTR subtype 2) [147, 148], inter-
cellular adhesion molecule-1 [149], and chemokine receptors
[150]. In addition to localization by targeting surface proteins,
internalization of probes through phagocytosis by macro-
phages can also detect such cells preferentially; several
nanoparticle-based and superparamagnetic probes show
promise in this regard [151].
Cell-based therapies, such as immunotherapy and stem cell
therapy, are most promising anticancer therapies; many forms
of adoptive T cell therapy are on the verge of being translated
to the clinic [43, 152, 153]. The development of therapeutic
strategies using tumour-targeted cells requires the ability to
image and determine in vivo the location, distribution and
viability of the therapeutic cells, as well as their biological fate
with respect to cell activation and differentiation. Such cell-
tracking methods, including labelling with, for example,
[111In]oxine, or magnetofluorescent techniques for cell label-
ling, play an important role in basic cancer research, where
they serve to elucidate novel biological mechanisms
[154–156].
In conclusion, it is expected that the material described,
which allows visualization of the biology of macrophages
and other immune cells in vivo in preclinical models, will also
be useful for a multitude of human applications. Because of
the implications of stromal cells and factors, this is an emerg-
ing field of potential targets for both imaging and therapy.
Imaging cell death
The currently most widely used therapy response criteria are
based on size measurements of tumour lesions according to
RECISTorWHO criteria [157]. However, lesion size changes
after therapy may take a long time to occur, and lesion size
may not always be reflective of actual response, i.e. eradica-
tion of tumour cells. Lesion size measurements are therefore
considered not to be ideal for early response assessment,
which is often desired in drug efficacy trials and treatment
monitoring. This has led to a high level of interest in nonin-
vasive methods for assessing tumour cell death following
interventions, allowing early therapy response assessment
[158].
Cell death is characterized by loss of cellular integrity that
is mediated by a large variety of molecular changes including:
externalization of phosphatidylserine to the outer leaflet of the
plasma membrane bilayer, activation of effector caspases, de-
polarization of the plasma and mitochondrial membranes and
loss of plasma membrane integrity [159, 160]. All these pro-
cesses have been studied as targets for imaging biomarkers
with the presentation of phosphatidylserine residues at the
outer surface of the plasma membrane being the most widely
studied to date [158, 161]. For this target, annexin-V-based
probes have been most frequently used, including probes suit-
able for imaging by MRI [162, 163], PET [164], SPECT
[165], optical techniques [166, 167] and ultrasound molecular
imaging [168]. However, despite promising results in clinical
trials [169, 170], suboptimal biodistribution profiles of
annexin-V tracers [171] have stimulated the search for other
molecules that can bind to phosphatidylserine [172–174].
As well as phosphatidylserine exposure, detection of cas-
pase activity has also been investigated as an imaging bio-
marker of cell death [175–178] and has even reached testing
in early clinical trials [179]. Besides these two main molecular
targets for cell death imaging, several other approaches are
also being evaluated as (surrogate) markers of cell death. The-
se involve imaging probes or imaging techniques that are able
to visualize membrane depolarization or loss of membrane
integrity. Regarding depolarization of membranes, triphenyl
phosphonium-based probes [68, 180, 181], and 2-(5-
fluoropentyl)-2-methyl malonic acid [182–184] have been
found to show uptake characteristics in tumour tissue that
could be linked to tumour cell death and reductions in tumour
volume as verified by other imaging techniques or ex vivo
analyses of tumour tissue.
Interest in two MRI techniques has recently been increas-
ing as a means to image processes related to tumour cell death:
diffusion-weighted (DW) MRI [185] and MRS of
hyperpolarized fumarate [186]. DWMRI provides image con-
trast through measurement of the diffusion properties of water
within tissues. By using sequential imaging with different
weightings for diffusion an apparent diffusion coefficient
(ADC) map can be generated. Water diffusion is restricted
within cells and increases following loss of cellular integrity
by which ADC DW imaging may be used to monitor cell
death. Various in vivo studies have shown significant correla-
tions between increases in ADC values in tumour tissue and
response to treatment and apoptosis of tumour cells
[187–190]. Due to loss of cellular integrity during cell death,
fumarate can enter cells rapidly and is converted to malate.
This process can be monitored by MRS of hyperpolarized [1,
4-13C2]fumarate [186]. The sensitivity of this latter technique
has even been shown to be superior to that of ADC DW
imaging [189].
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In conclusion, since eradication of tumour cells is the ulti-
mate goal of anticancer therapy, cell death detection is consid-
ered of high importance for (early) response assessment. Sev-
eral methods and probes are currently under investigation with
questions still remaining regarding the choice of relevant im-
aging target and the timing of assessment [1, 158, 191].
Multifunctional probes
Here we briefly introduce some concepts regarding multifunc-
tional imaging probes such as theranostic and multimodality
probes. As indicated above many of the molecular targets
mentioned are also suitable as targets for targeted therapy.
This has formed the basis for theranostics (theragnostics),
the principle by which the same targeting molecule or particle
can be used for both diagnosis and targeted therapy. This
principle has been exploited in peptide receptor radionuclide
therapy [9], but is also being considered a valuable strategy in
the development and use of other therapeutics, e.g. biologicals
and particle-based drug delivery systems such as liposomes,
microcapsules and polymeric micelles [192, 193].
Multimodality probes consist of compounds that carry
multiple signalling beacons by which they can be imaged by
two ormore imagingmodalities [194, 195]. These compounds
have the advantage that the strengths of different modalities
can be combined, e.g. high sensitivity and high spatial reso-
lution or quantitative performance, andmay specifically play a
role in image-guided drug delivery [193] and image-guided
surgery [196].
Specific challenges in preclinical imaging studies
Preclinical studies in animal models are important for the de-
velopment and evaluation of new imaging techniques and
imaging probes. However, data obtained in in vivo molecular
imaging studies in small animals may be influenced by the
animal model used, by animal preparation and handling, and
by the use of anaesthesia. Therefore, we briefly address some
important issues to be taken into account during small-animal
imaging in general (more detailed information can be obtained
from the literature [197]).
The use of multimodality imaging may be very demanding
for an animal, mostly because, in contrast to human studies,
imaging of small animals generally requires anaesthesia. It is
important to note that this may confound the results of imag-
ing studies, as anaesthesia may influence many physiological
parameters [198]. Such issues especially need to be taken into
account when multimodality imaging studies are performed at
regular time intervals. The feasibility of such studies is strong-
ly dependent on parameters such as the total acquisition time,
the type of anaesthesia administered, the surgical procedures
required per imaging session and the body temperature of the
anaesthetized animal, which depends on the use of a heated
bed before and during scanning. Imaging conscious animals
or imaging animals after death may avoid the issues with
anaesthesia, but these approaches clearly have their own in-
herent disadvantages and problems. For ultrasound imaging,
the type of carrier gas for isoflurane anaesthesia affects the
longevity of the microbubbles. Longevity of nontargeted
microbubbles is longer when medical air is used instead of
oxygen [199–201]; this might also have implications for
targeted microbubbles. On the other hand, longer persistence
of freely floating targeted microbubbles would also prolong
the ultrasound molecular imaging protocol as typically imag-
ing is not performed until most freely floating targeted
microbubbles are cleared from the circulation [73, 74]. How-
ever, new developments aiming at distinguishing adherent
from freely floating targeted microbubbles form an active area
of research.
Besides anaesthesia issues, ionizing radiation used in im-
aging studies can cause side effects and undesired antitumour
effects. In small-animal imaging, often relatively high
amounts of radioactivity have to be administered to produce
high-resolution images within a reasonable acquisition time.
In small-animal SPECT imaging, on a body weight basis, the
activity dose is therefore up to 100 times higher than in the
clinical setting. Funk et al. [202] estimated that the whole-
body dose in preclinical SPECT and PET studies ranges be-
tween 6 and 90 cGy in mice and between about 1 and 27 cGy
in rats. They concluded that the whole-body dose in small-
animal imaging can be very high in comparison to the lethal
dose to mice. The dose should therefore be monitored care-
fully and the administered activity should be kept to a mini-
mum. In follow-up SPECT/CT studies, the risk of side effects
due to high radiation doses from consecutive scanning must
be considered and dosimetry should be performed, and should
also include the radiation dose delivered by (repeat) CT scans
performed in SPECT/CT [203].Willekens et al. [204] estimat-
ed that the median organ dose in mice from a standard micro-
CT scan is about 40 cGy and this may influence the experi-
mental outcome, but adaptation of the scan protocol allows
accurate imaging without the risk of interfering with the ex-
perimental outcome of the study. Note that high-resolution
(high-dose) scanning can always be planned as a one-off scan
or as the final CT scan of a longer nuclear scan series.
Concluding remarks
We have described a panel of biological targets derived from
the Bhallmarks of cancer^ and indicated their potential for use
as imaging biomarkers in oncology based on data obtained
from preclinical studies in animal tumour models. Such
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preclinical studies are crucial in providing proof-of-concept in
the development process of new imaging biomarkers for di-
agnostic, prognostic or early response monitoring purposes in
patients. Furthermore, the use of imaging biomarkers in the
preclinical setting is also of value in the evaluation of new
drugs and tracers. It allows high-throughput assessment of
basic safety, pharmacokinetics and target specificity of the
compound of interest before clinical testing. While proof-of-
concept has been provided for some of the described imaging
biomarkers, the majority still need further validation at both
the preclinical and clinical level before they can qualify as
robust imaging biomarkers.
Therefore, driven by medical need the search for new or
improved imaging targets, imaging probes and (multimodal)
imaging technologies will continue. Multimodality imaging is
a promising new area in this respect. Recent imaging advances
are synergistic with new imaging agents, reporters, better
models and labelling options, so finally it is hoped that mo-
lecular imaging systems will allow clinicians to routinely ‘see’
expression and activity of specific molecules, cells and/or bi-
ological processes influencing tumour behaviour, that will an-
swer important questions to ultimately offer cancer patients
treatment tailored to their individual characteristics.
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